Literature DB >> 16530421

The use of mifepristone in the treatment of neuropsychiatric disorders.

Charles DeBattista1, Joseph Belanoff.   

Abstract

Mifepristone is a potent glucocorticoid and progesterone receptor antagonist. The pathophysiology of a number of neuropsychiatric disorders implicates abnormalities in glucocorticoid function. These include mood disorders such as psychotic major depression and bipolar depression. In addition, cognitive disorders such as Alzheimer's disease might also be partially mediated by abnormalities in the hypothalamic-pituitary-adrenal axis. Preliminary studies suggest that mifepristone might have a role in the treatment of a number of neuropsychiatric disorders.

Entities:  

Mesh：

Substances：

Year:  2006        PMID： 16530421     DOI： 10.1016/j.tem.2006.02.006

Source DB:  PubMed          Journal:  Trends Endocrinol Metab        ISSN： 1043-2760            Impact factor:   12.015


  27 in total

1.  Longitudinal changes in cortisol secretion and conversion to psychosis in at-risk youth.

Authors:  Elaine F Walker; Patricia A Brennan; Michelle Esterberg; Joy Brasfield; Brad Pearce; Michael T Compton
Journal:  J Abnorm Psychol       Date:  2010-05

2.  Persistent disruption of a traumatic memory by postretrieval inactivation of glucocorticoid receptors in the amygdala.

Authors:  Sophie Tronel; Cristina M Alberini
Journal:  Biol Psychiatry       Date:  2007-01-03       Impact factor: 13.382

Review 3.  Divergent regulation of distinct glucocorticoid systems in alcohol dependence.

Authors:  Scott Edwards; Hilary J Little; Heather N Richardson; Leandro F Vendruscolo
Journal:  Alcohol       Date:  2015-04-30       Impact factor: 2.405

4.  Postnatal glucocorticoid-induced hypomyelination, gliosis, and neurologic deficits are dose-dependent, preparation-specific, and reversible.

Authors:  Muhammad T K Zia; Govindaiah Vinukonda; Linnea R Vose; Bala B R Bhimavarapu; Sanda Iacobas; Nishi K Pandey; Ann Marie Beall; Preeti Dohare; Edmund F LaGamma; Dumitru A Iacobas; Praveen Ballabh
Journal:  Exp Neurol       Date:  2014-09-28       Impact factor: 5.330

Review 5.  Hormone treatment of depression.

Authors:  Russell T Joffe
Journal:  Dialogues Clin Neurosci       Date:  2011       Impact factor: 5.986

Review 6.  Inflammatory mediators of cognitive impairment in bipolar disorder.

Authors:  Isabelle E Bauer; Michaela C Pascoe; Bianca Wollenhaupt-Aguiar; Flavio Kapczinski; Jair C Soares
Journal:  J Psychiatr Res       Date:  2014-05-02       Impact factor: 4.791

7.  Stress and IL-1beta contribute to the development of depressive-like behavior following peripheral nerve injury.

Authors:  G J Norman; K Karelina; N Zhang; J C Walton; J S Morris; A C Devries
Journal:  Mol Psychiatry       Date:  2009-09-22       Impact factor: 15.992

Review 8.  Hypothalamic-pituitary-adrenocortical axis dysfunction in epilepsy.

Authors:  Aynara C Wulsin; Matia B Solomon; Michael D Privitera; Steve C Danzer; James P Herman
Journal:  Physiol Behav       Date:  2016-05-16

9.  Preclinical assessment for selectively disrupting a traumatic memory via postretrieval inhibition of glucocorticoid receptors.

Authors:  Stephen M Taubenfeld; Justin S Riceberg; Antonia S New; Cristina M Alberini
Journal:  Biol Psychiatry       Date:  2008-08-16       Impact factor: 13.382

10.  Early life stress as an influence on limbic epilepsy: an hypothesis whose time has come?

Authors:  Amelia S Koe; Nigel C Jones; Michael R Salzberg
Journal:  Front Behav Neurosci       Date:  2009-10-05       Impact factor: 3.558
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.